or red blood cells or platelets. But in CCUS they do not have the bone marrow morphology that is specific for MDS,” Dr. Venugopal explained. On average, she said, patients get diagnosed at 68-70 years ...

The immune systems of cancer patients are highly disrupted, with those who have a higher number of immune cells in their ...

Cells treated with ibrutinib and acalabrutinib each had a unique set of 13 m/z signals, which opens up the possibility of studying these metabolites as biomarkers of therapeutic response.

The immune systems of cancer patients are highly disrupted, with those who have a higher number of immune cells in their blood having a better survival rate, finds a new study that uses a pioneering ...

Panelists discuss exciting updates on Bruton tyrosine kinase (BTK) inhibitors from the 2024 American Society of Hematology ...

In the subgroup with 17p deletion or TP53 mutation, zanubrutinib outperformed others with the most favorable HR (0.52) and the highest SUCRA value of 97%.

The CRISTALLO trial showed that venetoclax plus obinutuzumab achieved high minimal residual disease negativity as a frontline chronic lymphocytic leukemia therapy.

In early clinical trials, small-molecule inhibitors of the B-cell signal transduction have demonstrated improvement in response rates in elderly patients with CLL, suggesting that they may become ...

Expert Rev Hematol. 2013;6(4):441-449. In conclusion, although age should generally determine the goal of treatment in CLL, the patient's functional status rather than chronological age can be ...

Defective mitochondrial function affected all T-cell subsets in patients with untreated CLL and worsened with progression of disease ... according to results from a study published in Blood Advances.